Immuno-oncology combinations: raising the tail of the survival curve

There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small cell lung cancer, immune checkpoint inhibitors also appear to have significant a...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Samuel J., Brown, Jessica, Lopez, Juanita, Yap, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944548/
https://www.ncbi.nlm.nih.gov/pubmed/27458526
http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944548/
https://www.ncbi.nlm.nih.gov/pubmed/27458526
http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0015

Ejemplares similares